Tim FerrissCutting-Edge Science for Eye Health — Dr. Jeffrey Goldberg
CHAPTERS
- 0:00 – 0:37
Why “irreversible” blindness may soon be reversible
Dr. Jeffrey Goldberg opens by challenging a long-held glaucoma paradigm: that lost vision can’t be recovered. He says the field is nearing unexpected, unprecedented levels of vision restoration.
- •Glaucoma is described as the number one cause of irreversible blindness worldwide
- •Traditional approach has been prevention and slowing progression, not restoring lost vision
- •He predicts the “irreversible” framing is about to be overturned
- •He signals rapid progress toward true vision restoration
- 0:37 – 4:01
Presbyopia as the personal entry point: readers, identity, and “addicting” crisp vision
Tim Ferriss frames the episode around his own near-vision decline and the search for cutting-edge presbyopia options. Dr. Goldberg shares a story about discovering readers and how quickly people can become psychologically attached to clearer vision.
- •Tim describes presbyopia as age-related near-vision decline and a personal ‘crisis of meaning’ around eyesight
- •Dr. Goldberg explains lens stiffening around age 40 as a common cause of presbyopia
- •He recounts accidentally trying readers and realizing how much better he could see
- •They discuss how “good vision is addicting,” setting up later discussion of dependence vs progression
- 4:01 – 6:49
Training supranormal vision: reduced frame-rate goggles and athletic performance
Dr. Goldberg explains why many professional athletes have better-than-20/20 vision and explores whether it can be trained. He describes glasses that remove visual information (by dimming frames) to train faster visual processing and hand–eye coordination.
- •Pro athletes often show sharper vision and faster reflex time than average
- •“Supranormal” vision is framed as moving from normal to better-than-normal performance
- •Cones are described as having a refresh rate around 30–60 frames per second
- •Glasses can dim visual input periodically, forcing adaptation and improving performance when returned to full vision
- 6:49 – 9:24
Eye drops for presbyopia: from indigenous anecdotes to FDA-approved pupil constriction
Tim mentions indigenous eye-drop practices and asks about modern pharmacologic options. Dr. Goldberg explains FDA-approved drops that improve near vision by constricting the pupil (via the iris), creating a pinhole-like effect that reduces refractive error.
- •Tim brings up indigenous eye drops used for distance vision in hunting contexts
- •Pilocarpine is discussed in the context of presbyopia-related drops
- •Dr. Goldberg clarifies the mechanism is primarily iris-driven pupil constriction, not lens flexibility
- •Pinhole optics can improve vision by making incoming light more tolerant of refractive error
- 9:24 – 16:48
Eye anatomy 101: cornea to retina to optic nerve
At Tim’s request, Dr. Goldberg gives a practical overview of how the eye is structured and how vision signals reach the brain. He walks through major components and where common issues like floaters arise.
- •Light path: cornea → pupil/iris → lens → vitreous → retina
- •Lens provides fine focusing and stiffens with age, contributing to presbyopia
- •Vitreous changes with age and is where floaters originate
- •Rods and cones convert photons into electrical signals; retinal ganglion cells send signals via the optic nerve to the brain
- 16:48 – 20:37
Supplements and emerging augmentation: AREDS2, CoQ10, ginkgo, and vitamin B3 trials
Tim describes taking AREDS2 and asks about low-downside approaches. Dr. Goldberg distinguishes proven uses from speculative ones and highlights vitamin B3 (nicotinamide) as an active area, including clinical trials exploring vision restoration in glaucoma.
- •AREDS2 is described as clinically proven to slow vision loss in moderate age-related macular degeneration
- •Dr. Goldberg notes lack of strong proof for benefits outside studied populations, though it’s ‘probably not gonna hurt’
- •CoQ10 and ginkgo are mentioned as supplements some patients take with limited evidence
- •Vitamin B3 (nicotinamide) is highlighted as a major topic with international trials, including in glaucoma
- 20:37 – 24:01
Vision training, brain plasticity, and what makes training work
Tim describes a rapid visual-perception training program and asks whether non-surgical approaches can help. Dr. Goldberg says there’s meaningful data in visual training, especially when it requires a motor response, and connects the topic to psychedelics and plasticity research.
- •Tim describes adaptive training using brief flashes and blur discrimination and reports perceived near-vision improvement
- •Dr. Goldberg says training effects are stronger when paired with a behavioral/motor output (button press, pointing, action)
- •He links the retina and optic nerve to the central nervous system and broader brain plasticity mechanisms
- •He notes growing interest in psychedelics/microdosing for reopening plasticity, while emphasizing uncertainty about dosing and protocols
- 24:01 – 26:59
Concussion and TBI: visual symptoms and neuro-rehab exercises
Dr. Goldberg describes concussion/TBI as a continuum with prominent visual symptoms that can be debilitating. He says limited clinical studies suggest targeted visual perception exercises can help rehabilitation, supporting the broader case for eye–brain plasticity training.
- •Concussion/TBI often affects vision, focus, and sleep, with major impacts on school and work
- •He notes visual rehab exercises show positive effects in limited clinical studies
- •The discussion bridges ‘injured to normal’ recovery to the possibility of ‘normal to supranormal’ training
- •He suggests searching for terms like concussion, neurorehabilitation, plasticity, and visual perception exercises, and emphasizes evaluating source credibility
- 26:59 – 31:31
Light-based interventions: red/violet light, myopia control, and mitochondria hypotheses
Tim asks about red and violet light therapies for eye health and myopia progression. Dr. Goldberg says disease-state data are strong in some areas (including FDA-approved red-light therapy for macular degeneration) and describes minutes-per-day dosing signals, while cautioning that best practices aren’t fully established.
- •Myopia is defined as nearsightedness and described as a major and growing problem
- •Dr. Goldberg says small daily doses of red light can slow myopia progression in young people, and violet light may also work
- •Mitochondrial dysfunction is linked to many neurodegenerative diseases of eye and brain
- •He emphasizes uncertainty around ideal dose/brightness and cautions against overconfident consumer adoption without more data
- 31:31 – 34:06
Vision loss, cognition, and depression—and why correcting vision can reverse decline
Tim asks whether vision loss correlates with cognitive decline similarly to hearing loss associations in dementia. Dr. Goldberg strongly affirms the correlation and adds that restoring vision—such as with cataract surgery—can reverse significant cognitive decline and depression symptoms in older adults.
- •A correlation between vision loss and cognitive decline is described as supported by foundational research
- •Vision is framed as the biggest input sense, with extensive brain resources dedicated to processing it
- •Vision decline is tied to depression, mental health, and anxiety pathways
- •Dr. Goldberg says cataract surgery restoring vision can reverse significant cognitive decline and/or depression in some older individuals
- 34:06 – 35:43
Presbyopia progression and the myth of “reader dependence”
Tim raises concerns that wearing readers might accelerate dependence and magnification needs. Dr. Goldberg dispels this, saying progression happens whether or not readers are used, and calls dependence largely psychological—once people experience crisp vision, they want it.
- •Lens stiffening from about age 40 to ~60 drives predictable increases in required reader strength
- •He says people will progress through strengths whether they wear readers or not
- •He recommends wearing readers rather than struggling
- •Dependence is characterized as psychological: people prefer the clarity once experienced
- 35:43 – 41:20
Visual-system devices for the brain: Cognito-style stimulation, retinal cell types, and ‘sweet spot’ activity
Tim brings up a flashing light and sound headset approach aimed at influencing Alzheimer’s-related pathology. Dr. Goldberg expands to a broader framework: visual inputs can shape brain activity, and the right level of neural electrical activity supports plasticity and responsiveness to growth factors; he describes targeted retinal stimulation concepts (e.g., motion-direction cues).
- •Tim describes a headset using flashing lights and audio intended to drive brain rhythms in cognitive disease contexts
- •Dr. Goldberg discusses how both too much and too little neural activity are harmful, arguing for a ‘sweet spot’ to promote plasticity
- •He explains retinal cell response categories (on/off, color-opponent, motion/direction sensitive)
- •He describes using motion-like visual stimuli (e.g., a ‘flying through stars’ cue) to engage specific retinal pathways and study effects on degeneration and performance
- 41:20 – 46:30
Glaucoma fundamentals: risk factors, eye-pressure variability, and cannabis mechanics
Dr. Goldberg defines glaucoma as a common neurodegenerative disease affecting retinal ganglion cells and the optic nerve. He explains key risk factors (age and eye pressure), highlights diurnal variability in pressure measurement, and addresses cannabis as a commonly asked-about pressure-lowering option with practical limitations and ongoing compound isolation work.
- •Glaucoma is described as a leading neurodegenerative disease causing irreversible vision loss via optic nerve degeneration
- •Risk rises with age; family history increases risk substantially compared to baseline
- •Eye pressure varies short-term and long-term, including diurnal cycles that can confound measurements
- •Cannabis can lower eye pressure, but the effect is time-limited; efforts exist to isolate non-intoxicating compounds and develop eye-drop delivery
- 46:30 – 54:07
Stem cells, immune involvement, and the microbiome axis in eye disease
Tim asks about stem cells and then pivots to inflammation and immune mechanisms. Dr. Goldberg says retinal ganglion cells can be grown from human stem cells and early animal-model transplantation work is progressing, but warns against premature commercial clinics; he then details evidence that innate immunity and the microbiome can be central drivers in glaucoma-like degeneration in animal models.
- •Dr. Goldberg says progress is being made growing retinal ganglion cells from human stem cells and exploring transplantation in animals
- •He warns patients not to pay for unproven ‘stem cell’ clinic interventions
- •He says evidence increasingly implicates innate immunity in neurodegenerative eye diseases, including glaucoma and macular degeneration
- •He describes experiments in which germ-free mice show different glaucoma damage outcomes after pressure elevation, highlighting immune-system mediation and motivating targeted immune-modulating therapies
- 54:07 – 1:03:37
Metabolic syndrome, GLP-1 receptor agonists, microbiome sharing—and dry eye basics
They discuss mixed findings on diabetes/metabolic syndrome links to glaucoma progression, then shift to GLP-1 receptor agonists as a major converging topic for metabolic health and neuroprotection. Dr. Goldberg also talks about how microbiomes can be shared between people, and later addresses dry eye as the most common age-related eye disease, including preservative-free tears and serum tears.
- •Dr. Goldberg describes conflicting study signals on diabetes/metabolic syndrome and glaucoma, concluding overall effect may not be huge
- •GLP-1 receptor agonists are described as highly promising for reducing metabolic syndrome and potentially supporting neuroprotection
- •They discuss the broader nervous system–immune system–microbiome axis and speculate about future microbiome-based therapies, while cautioning about premature products
- •Dry eye is described as extremely common with age; he recommends preservative-free tears for frequent use and explains serum tears made from a patient’s own blood-derived serum to deliver growth factors
- 1:03:37 – 1:17:08
Screening and prevention: exams, UV protection, full-spectrum light, and the next paradigm shift
Dr. Goldberg offers practical screening guidance (especially with family history and diabetes) and emphasizes UV protection for slowing cataract development. He distinguishes full-spectrum light benefits (e.g., outdoor light slowing myopia development) from any need for UV exposure, then returns to the big thesis: restoration of vision (and potentially cognition) may become feasible as plasticity science, biotech investment, and translational trials converge.
- •He urges periodic eye exams, earlier/more frequent with family history; annual exams are emphasized for people with diabetes
- •UV protection via sunglasses or regular glasses is discussed as a simple way to reduce cataract risk; protective eyewear is recommended for injury risk settings
- •He says evidence supports benefits of full-spectrum light exposure (including for slowing myopia development), without evidence that UV itself is required
- •He predicts the major paradigm shift will be moving from slowing degeneration to restoring vision, enabled by advances in plasticity, cell therapy, neuroscience mapping, and increased translational investment
- 1:17:08 – 1:29:08
Mitochondria: supplements, transplant concepts, and metabolic screening priorities
Tim asks about mitochondria beyond red light, and Dr. Goldberg broadens mitochondria’s role (energy, signaling scaffolds, dynamics). They discuss vitamin B3’s metabolic links and the idea of mitochondrial transplant approaches, including embryo-related mitochondrial replacement; they then touch on screening measures tied to cognitive health, and the role of exercise as a high-leverage intervention.
- •Mitochondria are discussed as dynamic, communicative, and central to neurodegenerative disease mechanisms
- •Vitamin B3 (nicotinamide) is again tied to mitochondrial metabolism and signaling relevance
- •Dr. Goldberg mentions reports of mitochondrial transplants and discusses mitochondrial replacement concepts in embryos (leading to ‘three-parent’ framing)
- •He emphasizes lipids and blood pressure as key screening targets for long-term cognitive health, while noting there isn’t a great blood test for mitochondria yet
- •Exercise is framed as highest ROI when moving from none to some, rather than optimizing from some to more
- 1:29:08 – 1:36:02
How to participate in progress: clinical trials, trusted sources, and where to look
Dr. Goldberg closes by emphasizing that many promising ideas need proper science, and that patient participation is essential for answering what works. He and Tim point listeners to centralized trial listings and foundation resources, and Dr. Goldberg mentions Stanford Ophthalmology’s clinical trial listings as an additional pathway.
- •He encourages asking eye-care providers about clinical trials and emphasizes mutual gratitude between researchers and participants
- •He says trials are necessary to evaluate supplements, devices, red light, psychedelics, and microbiome approaches responsibly
- •He recommends searching ClinicalTrials.gov by disease to find recruiting studies and contacting sites to assess eligibility
- •He notes disease foundations often provide reliable patient-facing information and trial awareness resources
- •He points to Stanford Ophthalmology’s website for disease-by-disease clinical trial listings and contact details
